XNAS · Healthcare · Biotechnology
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | Q1 2026 | -0.18 | -0.18 | +0.00% | $0 | ➖ Inline | -1.29% | -18.45% | — |
| 2026-03-12 | Q4 2025 | -0.23 | -0.17 | +26.09% | $0 | ✅ Beat | +2.44% | -10.12% | +10.12% |
| 2025-11-06 |
| Q3 2025 |
| -0.23 |
| -0.19 |
| +17.39% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-13 | Q2 2025 | -0.27 | -0.23 | +14.81% | $0 | ✅ Beat | +0.00% | +1.92% | +8.65% |
| 2025-03-13 | Q4 2024 | -0.34 | -0.28 | +17.65% | $0 | ✅ Beat | +2.65% | -13.76% | -24.34% |
| 2024-11-07 | Q3 2024 | -0.33 | -0.32 | +3.03% | $0 | ✅ Beat | -3.45% | -22.88% | -28.84% |
| 2024-08-07 | Q2 2024 | -0.35 | -0.35 | +0.00% | $0 | ➖ Inline | -4.45% | -8.91% | -2.43% |
| 2024-05-13 | Q1 2024 | -0.41 | -0.38 | +7.32% | $22,000 | ✅ Beat | +2.07% | -10.69% | -11.38% |
Showing last 8 quarters.